HomeAbout JournalEditorial BoardSubmission GuidelinesSubscriptionContact UsChinese
Quote : 陈娟,徐琳本,蒋益兰,翦林宏,曾宏亮,谭小宁.健脾消癌方调控巨噬细胞M2极化对结直肠癌细胞侵袭作用的研究[J].湖南中医药大学学报英文版,2022,42(12):2002-2007.[Click to copy ]
【Print 】      【Download PDF 】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous |Next→ Archive    Advanced Search
This paper :Browser 3281times   Download 1482times
健脾消癌方调控巨噬细胞M2极化对结直肠癌细胞侵袭作用的研究
陈娟,徐琳本,蒋益兰,翦林宏,曾宏亮,谭小宁
(湖南省中医药研究院, 湖南 长沙 410006)
摘要:
    目的 探讨健脾消癌方调控巨噬细胞M2极化对结直肠癌HCT116细胞侵袭转移能力的影响。方法 使用佛波酯诱导THP-1细胞成M0型巨噬细胞,通过Transwell法构建HCT116细胞与M0型巨噬细胞共培养体系,设立空白血清对照组、健脾消癌方含药血清组、IL-4+空白血清组、IL-4+健脾消癌方含药血清组。RT-PCR法检测巨噬细胞M2极化相关基因C-C基序趋化因子22(C-C motif chemokine22, CCL22)、精氨酸酶-1(arginase-1, Arg-1)表达,Transwell法检测HCT116侵袭转移能力,Western blot法检测HCT116中E-钙黏蛋白(E-cadherin)、波形蛋白(Vimentin)及基质金属蛋白酶9(matrix metalloproteinase, MMP-9)蛋白表达水平。结果 与空白血清对照组比较,IL-4+空白血清组能上调CCL22、Arg-1表达(P<0.01),下调HCT116细胞E-cadherin表达、上调Vimentin、MMP-9表达(P<0.01),增加结直肠癌HCT116细胞侵袭数(P<0.01);与空白血清对照组比较,健脾消癌方含药血清组能下调CCL22、Arg-1表达(P<0.05),上调HCT116细胞E-cadherin表达(P<0.05),下调Vimentin表达(P<0.05),减少结直肠癌HCT116细胞侵袭数(P<0.01);与IL-4+空白血清组比较,IL-4+健脾消癌方含药血清组可下调CCL22(P<0.05)、Arg-1(P<0.01)表达,上调HCT116细胞E-cadherin表达(P<0.05),下调Vimentin、MMP-9表达(P<0.05),减少结直肠癌HCT116细胞侵袭数(P<0.01)。结论 健脾消癌方能一定程度上抑制巨噬细胞M2极化,阻断HCT116细胞上皮间质转化进程而抑制结直肠癌细胞侵袭转移。
关键词:  健脾消癌方  结直肠癌  巨噬细胞  M2极化  共培养  侵袭转移  上皮间质转化
DOI:10.3969/j.issn.1674-070X.2022.12.008
Received:July 23, 2022  
基金项目:国家自然科学基金项目(81774287); 湖南省自然科学基金项目(2020JJ4413); 湖南省教育厅科学研究项目(19C1412)
Effects of Jianpi Xiao'ai Formula on the invasion of colorectal cancer cells by regulating M2 polarization of macrophages
CHEN Juan,XU Linben,JIANG Yilan,JIAN Linhong,ZENG Hongliang,TAN Xiaoning
(Hunan Academy of Chinese Medicine, Changsha, Hunan 410006, China)
Abstract:
    Objective To investigate the effects of Jianpi Xiao'ai Formula on the invasion ability of HCT116 colorectal cancer cells by regulating macrophage M2 polarization.Methods THP-1 cells were induced to M0 macrophages by phorbol ester. Then, HCT116 cells and M0 type macrophages were co-cultured by Transwell. The co-cultured cells were randomly divided into blank serum control group, Jianpi Xiao'ai Formula serum group, IL-4 + blank serum group, and IL-4 + Jianpi Xiao'ai Formula serum group. The RT-PCR was used to detect the expression of C-C motif chemokine22(CCL22) and arginase-1(Arg-1), the related genes of M2 polarization in macrophages, and Transwell was applied to detect the invasion and metastasis of HCT116. The expression levels of E-cadherin, Vimentin and matrix metalloproteinase(MMP-9) in HCT116 were determined by Western blot.Results Compared with blank serum control group, IL-4 + blank serum group could up-regulate the expression of CCL22 and Arg-1(P <0.01), down-r egulate the expression of E-cadherin and up-regulate the expression of Vimentin and MMP-9 in HCT116 cells(P<0.01), and increased the invasion number of colorectal cancer HCT116 cells(P<0.01). Compared with blank serum control group, Jianpi Xiao'ai Formula serum group showed the lower expression of CCL22 and Arg-1(P<0.05), higher E-cadherin expression in HCT116 cells(P<0.05), lower Vimentin expression(P<0.05), and less colorectal cancer HCT116 cell invasion(P<0.01). Compared IL-4 + blank serum group, IL-4 + Jianpi Xiao'ai Formula serum group could down-regulate CCL22(P<0.05), and Arg-1 expression(P<0.01), up-regulated E-cadherin expression in HCT116 cells(P<0.05), down-regulated the expression of Vimentin and MMP-9(P<0.05), and decreased the number of colorectal cancer HCT116 cell invasion(P<0.01).Conclusion Jianpi Xiao'ai Formula could inhibit M2 polarization of macrophages, block EMT process of HCT116 cells and inhibit the invasion and metastasis of colorectal cancer cells.
Key words:  Jianpi Xiao'ai Formula  colorectal cancer  macrophage  M2 polarization  co-culture  invasion and metastasis  epithelial-mesenchymal transition
本文二维码信息
二维码(扫一下试试看!)
Adress:No. 300, Xueshi Road, Hanpu Science and Education Park, Yuelu District, Changsha City, Hunan Province(410208)    Telephone0731-88458947     E-mail:xuebaotcm@126.com
Technical support :Beijing Qinyun Technology Development Co., Ltd